Ulas Bayraktar, MD
Hematology & Oncology · Hurricane, WVNPI 1528267952
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.8% of the total across 56 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 13.1% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for hematology & oncology clinicians in WV, where the typical reported total is $1,186.
Across 56 payments — averaging $22.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$161
- AstraZeneca$118
- E.r. Squibb & Sons, L.L.C.$109
- Bristol Myers Squibb$101
- Pharmacyclics LLC, An Abbvie Company$83
- Pfizer$76
- plus $584 from 20 others
What the payments were for
- Food & beverage$1,20698%
- Education$272%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 7 | $161 |
| AstraZeneca | 5 | $118 |
| E.r. Squibb & Sons, L.L.C. | 6 | $109 |
| Bristol Myers Squibb | 5 | $101 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $83 |
| Pfizer | 4 | $76 |
| Merck | 4 | $63 |
| Johnson & Johnson | 3 | $63 |
| Jazz Pharmaceuticals Inc. | 1 | $54 |
| Regeneron Healthcare Solutions, Inc. | 2 | $52 |
| Genentech USA, Inc. | 2 | $52 |
| Sanofi | 2 | $36 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Foundation Medicine, Inc. | 1 | $23 |
| Rigel Pharmaceuticals, Inc. | 1 | $23 |
| Seagen Inc. | 1 | $23 |
| Beigene USA, Inc. | 1 | $22 |
| Array Biopharma Inc | 1 | $20 |
| GSK | 1 | $19 |
| Astellas Pharma US Inc | 1 | $18 |
| Bayer | 1 | $17 |
| Recordati_rare_diseases_inc. | 1 | $17 |
| Gilead | 1 | $16 |
| Incyte Corporation | 1 | $14 |
| AbbVie | 1 | $14 |
| Puma Biotechnology, Inc. | 1 | $12 |
How this compares
$1,233 in reported general payments places this provider in the 50th percentile of 72 hematology & oncology providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 12 | $190,387 |
| VenclextaVenetoclax | 15 | $160,273 |
| EliquisApixaban | 26 | $23,937 |
| Ondansetron Hcl | 33 | $2,463 |
| Anastrozole | 35 | $460 |
| Prochlorperazine Maleate | 23 | $276 |
| Dexamethasone | 17 | $256 |
| Acyclovir | 15 | $194 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 15 | $14 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis | $76 | $214,32438 claims |
| AbbVieVenclexta | $14 | $160,27315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 72 hematology & oncology providers in West Virginia.
Other hematology & oncology in Hurricane
- Damian SilberminsHuntington$277K
- Abraham KanateMorgantown$169K
- Salman OsmanBridgeport$118K
- Ashkan EmadiMorgantown$88K
- Konstantinos SdrimasMorgantown$81K
- Arvinder BirHuntington$74K
- Bhavana BhatnagarWheeling$72K
- Ihtishaam QaziMorgantown$18K
- Matias ValsecchiHuntington$17K
- Sonikpreet AulakhMorgantown$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.